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Introduction:  The  continuous  subcutaneous  insulin  infusion  (CSII)  is an  alternative  to multiple  daily  injec-
tions therapy  in  type  1 diabetes  and  its  use  is increasingly  common  due  to the  beneﬁcial  effects  on  glucose
control.
Aims:  To  analyze  clinical  features  and  biochemical  parameters  of patients  on CSII  therapy.
Type of study:  Longitudinal  retrospective.
Setting: Outpatient  clinic.
Population:  Type  1 diabetic  patients  using  insulin  infusion  pump  in  our department.
Methods:  We  evaluated  outcomes  regarding  the following  set  points:  immediately  before  initiation  of
CSII  therapy,  12  months  after  inclusion  and  in  the last  appointmentHH.  For  statistical  analysis,  we used
non-parametric  tests  and  linear  regression  analysis.  We  considered  signiﬁcant  a value  of  p≤0.05.
Results:  We  studied  63  patients  (24 men;  39  women)  with  a mean  pre-CSII  HbA1c  of 8.2%  ± 1.43;  mean
age  at  the time  of placement  of  32.7  ±  10.94  years;  and  mean  follow  up  time  after  placement  of  2.1  ±
1.92  years.  There  was  a statistically  signiﬁcant  reduction  of  HbA1c  during  follow-up  (HbA1c  12 months:
7.2%  [6.6–7.8]  p  = 0.001;  HbA1c  at the  end  of  follow-up:  7.4%  [6.6–7.9]  p = 0,001).  There  was  no signiﬁcant
variation  of  weight  or  total  daily  insulin  dose.  We  registered  a negative  correlation  between  the last  HbA1c
before CSII  and  the  reduction  in HbA1c  until  the  end  of  the follow-up  period  (=−0.644  p = 0.000).  The
median  reduction  in HbA1c  was  higher  in  women  (W: –1.10  [−2.20––0.40]  vs  M:  −0.10  [−0.80–0.40];
p  =  0.002).  Female  gender  was  a predictive  factor  of better  results  with  CSII,  even  after  adjustment  to  the
last HbA1c  before  the  initiation  of therapy.
Conclusions:  In our sample,  the  last  HbA1c  before  the  beginning  of  CSII  was  the  most  powerful  predictive
factor  of  the reduction  of HbA1c  during  follow  up.  Women  had  better  results  than  men.  There  was  no
signiﬁcant  variation  of weight  and  total  daily insulin  dose  during  follow  up.
©  2014  Sociedade  Portuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Published  by  Elsevier
España,  S.L.U.  This  is  an  open  access  article  under  the CC BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Evoluc¸ ão  do  controle  metabólico  e  do  peso  após  início  de  terapêutica
de  infusão  subcutânea  contínua  de  insulina
r  e  s  u  m  oalavras chave:
omba de infusão subcutânea de insulina
iabetes mellitus tipo 1
ênero
Introduc¸ ão:  A terapêutica  com  infusão  subcutânea  contínua  de  insulina  (Tisi)  é uma  opc¸ ão  ao  uso  de
múltiplas  injec¸ ões  de  insulina  na diabete  tipo  1 e o seu  uso  é cada  vez  mais  frequente  dados  os  benefícios
no  controle  glicêmico.
Objetivos: Analisar  as  características  clínicas  e os  parâmetros  bioquímicos  dos doentes  tratados  com  Tisi
e procurar  fatores  preditores  da resposta  à terapêutica.
Tipo de  estudo:  Longitudinal  retrospectivo.
Local: Consulta  externa.
Populac¸ ão:  Diabéticos  tipo 1  usuários  de Tisi  seguidos  no  nosso  servic¸ o.
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Métodos:  Foram  registrados  os  resultados  nos  seguintes  períodos:  imediatamente  antes  da colocac¸ ão
da  Tisi,  12 meses  após  colocac¸ ão  e à data da  última  consulta.  Os resultados  foram  apresentados  como
média  ±  desvio  padrão  ou mediana  [quartis].  Foram  usados  testes  não  paramétricos  para  a análise  estatís-
tica  e foi efetuada  regressão  linear.  Foram  considerados  signiﬁcativos  os  valores  de p < 0,05.
Resultados:  A  amostra  era  constituída  por 63 diabéticos  tipo 1 (24  homens  - H;  39 mulheres  - M)  com
os  seguintes  valores  antes  da colocac¸ ão:  idade  32,7  ± 10,94 anos;  HbA1c  8,2%  ±  1,43.  O tempo  médio
de  catamnese  foi  de 2,1 ± 1,92 anos.  Ocorreu  uma  reduc¸ ão estatisticamente  signiﬁcativa  da  HbA1c  ao
longo do tempo  de  seguimento  (HbA1c  aos  12 meses:  7,2%  [6,6-8]  p =  0,001;  HbA1c ao  ﬁm  do  tempo  de
seguimento:  7,4%  [6,6,7,9]  p = 0,001).  Não  se veriﬁcou  variac¸ ão  do peso  e da dose  diária  total  de  insulina.
Veriﬁcou-se  uma  correlac¸ ão  negativa  entre  a HbA1c  prévia  e  a reduc¸ ão da  HbA1c  até  ao ﬁm  do  tempo
de seguimento  (= −0,644  p =  0,000).  A  mediana  da  reduc¸ ão da  HbA1c  até  a data  da última  consulta  foi
maior  no  grupo  das  mulheres  (M:  −1,10  [−2,20  - −0,40]  vs. H: −0,10  [−0,80  -  −0,40];  p  = 0,002).  O  gênero
feminino  foi  um  fator  preditivo  de  melhor  resposta  à Tisi  mesmo  após  ajuste  para  a HbA1c  prévia.
Conclusões:  : Na  amostra  estudada,  a última  HbA1c  anterior  ao  início  da  Tisi  foi  o  fator  com  maior  capaci-
dade de  predic¸ ão  da  resposta  à  terapêutica.  As  mulheres  obtiveram  melhores  resultados  da  terapêutica
com  Tisi  do que  os homens.  Não  ocorreram  variac¸ ões  estatisticamente  signiﬁcativas  do  peso  ou  da  dose
diária total  de  insulina.
© 2014  Sociedade  Portuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Publicado  por  Elsevier
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Resultsntroduction
After the publication of the DCCT1, the goal of the treatment
f type 1 diabetes mellitus is to obtain glucose values as near as
ossible to normal, as long as the patient’s hypoglycaemia risk isn’t
nacceptably high. The optimum glucose control would prevent
he occurrence of chronic complications of diabetes2 and result in
mprovement of the quality of life of the person with diabetes3. The
eview of target glucose values in type 1 diabetes mellitus has led to
he increased use of intensive insulin therapy that was suggested by
he same study as the most effective method to obtain the proposed
oals.
Continuous subcutaneous insulin infusion (CSII) therapy is an
lternative to the use of multiple daily injections (MDI) for the treat-
ent of type 1 diabetes mellitus and its use is increasingly common
ue to the beneﬁcial effects on glucose control. Pickup4 used CSII
s a research tool to elucidate the relation between glucose control
nd diabetic complications. Later on, other authors described the
mprovement of glucose control in selected and motivated patients
hat previously had not attained the treatment goals with MDI. 5–11.
lthough several studies showed signiﬁcant reductions in HbA1c
ith CSII, a metanalysis of randomized clinical trials comparing
ith MDI  showed, by a random effects model, a non-signiﬁcant
rend towards mean reductions in HbA1c of −0.26 (IC 95% –0.57-
.05) after 6 months follow up and −0.61 (IC 95% −1.29–0.07) after
2 months follow up7. Other authors12 detected signiﬁcant reduc-
ions in HbA1c (9.36 ± 0.22 vs 8.96 ± 0.11, p = 0.039). Signiﬁcant
ifferences between therapeutic modalities are only apparent with
ollow up periods longer than 1 year.
Regarding hypoglycaemia risk, several observational studies
uggest that CSII is associated with a signiﬁcant risk reduction, par-
icularly in terms of severe episodes7. The same metanalysis did not
nd data supporting sustained reductions in total daily insulin dose
TDID) in patients using CSII, nor signiﬁcant reductions in weight.
ther authors12,13 suggest that CSII might be associated with as
uch as 16% reductions in TDID comparing with multiple daily
njections, as well as a signiﬁcant increase in weight (68.2 ± 0.7 Kg
s 71.2 ± 0.3 Kg; p < 0.001).
Greater patient satisfaction has been documented in patients
sing CSII therapy, although there is discordance between studies
n terms of impact on quality of life3,6,7,14. However, it is of note that
SII therapy might be associated with other complications, namely
n increase in risk of diabetic ketoacidosis, pump malfunction and
nfusion site infections12. Few studies have analyzed the variables
ssociated with improved metabolic control after initiation of CSIIEspaña,  S.L.U.  Este  é um  artigo  Open  Access  sob  a licença de  CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
therapy. Two studies have shown greater beneﬁt in individuals with
higher HbA1c before CSII15,16. The selection of patients with higher
HbA1c (HbA1c > 8.0%) was associated with superior beneﬁt than
described in two metanalysis12,13.
There is no signiﬁcant data regarding the effect of age in CSII but
several authors have suggested good results in pediatric patients
in terms of HbA1c reduction as well as in risk of hypoglycaemia
and quality of life17. One study on female adolescents showed a
good response to CSII therapy in this population, which included
individuals with eating disorders18.
Aims
To analyze the clinical characteristics and biochemical parame-
ters in diabetic patients treated with CSII therapy and identify the
predictive factors for a good response to this regimen.
Methods
We included all individuals with type 1 diabetes that were users
of CSII, under follow up in the Endocrinology consultation of our
hospital. We  recorded variables in the following time points: imme-
diately before initiation of CSII therapy, 12 months after initiating
use of the insulin pump and at the time of the last appoint-
ment. As the TDID is not recorded in the patient’s clinical ﬁle, it
was inferred from the insulin sensitivity factor, which is calcu-
lated using the 1800 rule, universally used in our consultation.
Results were presented as mean ± standard deviation or median
[quartiles]. Changes in weight, TDID and TDID/Weight ratio were
calculated as fractions. For the statistical analysis, we used SPSS
Statistics 20.0. To compare differences in the variables and their
correlations we used the Wilcoxon test, Mann-Whitney test, Spear-
man correlation and a linear regression model. We  considered
signiﬁcant a value of p≤0.05. In a separate analysis, the sample was
divided in two  groups (better and worse response) according to
the median of variation in HbA1c at the end of follow up (−0.8%),
and we used the Mann-Whitney and Fischer exact tests to compare
groups.The sample included 63 patients with type 1 diabetes (24 men;
39 women) whose clinical characteristics are presented in Table 1.
The mean follow up was  2.08 ± 1.920 years.
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Table 1
Characterization of the sample (n 63: 24♂ 39♀).
Age at diagnosis (years) 17.25 ± 10.811
Age at the time of initiation of CSII (years) 32.70 ± 10.942
Age (years) 35.63 ± 11.467
Duration of diabetes (years) at he time of
initiation of CSII
17.98 ± 9.006
Duration of follow up (years) 2.08 ± 1.920
Pre-CSII HbA1c (%) 8.167 ± 1.4277
HbA1c 12 months (%) 7.391 ± 1.1145
HbA1c at the end of follow up (%) 7.507 ± 1.2350
Pre-CSII weight (Kg) 72.27 ± 11.891
Weight 12 months (Kg) 67.52 ± 10.986
Weight at the end of follow up (Kg) 70.89 ± 14.678
Pre-CSII TDID (UI) 52.0168 ± 14.80194
TDID/Weight (UI/Kg) 0.73 ± 0.189
TDID 12 months (UI) 47.0371 ± 13.09964
TDID/Weight (UI/Kg) 0.66 ± 0.146
TDID at the end of follow up (UI) 48.8544 ± 19.10247
TDID/Weight (UI/Kg) 0.68 ± 0.185
TDID–total daily insulin dose
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a 0.824 reduction in HbA1c (t = −2.449; p = 0.018) and each 1.0%
increase of the pre-CSII HbA1c is associated with a 0.67% reduction
in HbA1c (t = -5.869; p = 0.000)–Table 3.
Table 3
Univariate linear regression models for pre-CSII HbA1c and gender. Multivariate
linear regression model including pre-CSII HbA1c and gender as independent covari-
ates and a dependent variable - change in HbA1c until the end of the follow up
period.
Univariate linear regression model
R2 Regression coefﬁcient t p
Pre-CSII HbA1c 0.465 −0.756 −6.593 0.000
Gender (female) 0.188 −1.413 −3.406 0.001
Multivariate linear regression model (R2 = 0.523)
T
C
RFigure 1. Scatter plot–pre-CSII HbA1c–Variation of HbA1c at the end of follow up.
General outcomes.  After CSII initiation, there was a signiﬁcant
ean HbA1c reduction at 12 months and at the end of the follow
p period (Table 2). There was no signiﬁcant variation in weight,
DID or TDID/weight ratio.
HbA1c.  We  found a signiﬁcant correlation between pre-CSII
bA1c and its variation at 12 months and at the end of follow up
=−0.643 p = 0.000 and =−0.644 p = 0.000, respectively)–ﬁgure 1.
he linear regression model showed that for each 1.0% increase
n pre-CSII HbA1c there is a 0.76% reduction in post-CSII HbA1c
R = 0,682, t = −6,593, p = 0,000). We  found a signiﬁcant correlation
etween HbA1c variation at 12 months and age at the time of
nitiation of CSII therapy (=0.312 p = 0.033) and between HbA1c
ariation at the end of follow up and age at diagnosis (=0.390 = 0.005) and pre-CSII TDID (=−0.402 p = 0.025). The total time
f follow up had a signiﬁcant correlation with pre-CSII HbA1c
=0.260 p = 0.049) and with the variation of HbA1c at 12 months
able 2
linical and biochemical outcomes after initiation of CSII.
Pre-CSII 12
HbA1c (%) 7.8 [7.23–8.78) 7.
Weight (Kg) 72.0 [53–98] 65
TDID  (UI) 50.0 [41.86–60.00] 45
esults of HbA1c and TDID are presented as median [1st quartile–3rd quartile] and weightFigure 2. Box plot–Gender differences in HbA1c variation until the end of the follow
up period.
and end of follow up (=−0.448 p = 0.002 e =−0.304 p = 0.028). The
linear regression model showed that the total time of follow up is
not a predictive factor of HbA1c variation at 12 month or at the end
of follow up, after adjustment to the pre-CSII (p = 0.403 e p = 0.106,
respectively).
Gender. In the comparative analysis, we found a signif-
icant difference in HbA1c variation until the end of follow
up, with a more pronounced reduction in women comparing
to men  (median [quartile]: −1.100 [−2.200–−0.400] vs −0.100
[−0.800–0.400]; p = 0.002)–ﬁgure 2. It is of note that the two
groups were not signiﬁcantly different in terms of pre-CSII HbA1c
(Men: 7.7 [7.2–8.2] vs Women: 8.2 [7.3–9.2]; p = 0.119).
We evaluated the interaction between pre-CSII HbA1c and gen-
der as determinants of variation of HbA1c until the end of the follow
up period. According to this model, these two variables predict
52.3% of the variance of HbA1c. Female gender is associated withRegression coefﬁcient t p
Gender −0.824 −2.449 0.018
Pre-CSII HbA1c −0.672 −5.869 0.000
 months End of follow up
2 [6.60–7.80] p = 0.001 7.4 [6.60–7.90] p = 0.001
.0 [51–94] p = 0.103 67.0 [52–105] p = 0.721
.0 [40.02–52.94]p = 0.102 45.0 [36.00–56.25]p = 0.420
 is presented as median [minimum–maximum]. p <0,05 was considered signiﬁcant.
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Weight and TDID. We  found a signiﬁcant correlation between
eight and TDID, and between the weight variation and TDID varia-
ion until the end of the follow up period (=0.557 p = 0.031). There
s a signiﬁcant correlation between pre-CSII TDID and its varia-
ions at 12 months and end of follow up (=−0.561 p = 0.005 and
=−0.619 p = 0.001, respectively), as well as with pre-CSII HbA1c
nd HbA1c variation until the end of follow up (=0.381 p = 0.024
nd =−0.402 p = 0.025, respectively). The pre-CSII TDID/weight
atio has a signiﬁcant correlation with the variation in TDID/weight
atio until the end of follow up (=−0.771 p = 0.001).
Characterization of groups according to the quality of
esponse.  The sample was divided in two groups according to the
edian HbA1c variation until the end of follow up: a reduction in
bA1c > 0.8% was considered a «better response» (BR) and a reduc-
ion in HbA1c inferior or equal to 0.8%, a stable HbA1c or an increase
n HbA1c were considered a «worse response» (WR). When the two
roups were compared, we found a signiﬁcant difference between
re-CSII HbA1c (BR 8.65% [7.775-9.775] vs WR  7.30% [6.900–8.100];
 = 0.000), age at diagnosis (BR 10.0 years [5.5–18.0] vs WR 20.0
ears [12.25–26.0]; p = 0.003) and age at the time of CSII initia-
ion (BR 28.5 years [22.75–34.25] vs WR  33.0 years [27.5–41.5];
 = 0.028). We  found a signiﬁcantly higher number of women in the
roup with a BR to CSII (p = 0.017). There were no other signiﬁcant
ifferences between groups.
iscussion
In concordance with previous literature, we found a signiﬁcant
eduction in HbA1c after initiation of CSII, representing a median
ariation in HbA1c of −0.50% [−1.20–0.1] at 12 months follow up
nd −0.80% [−1.475–0.3] at the end of follow up. These results sug-
est that there is a more marked reduction in HbA1c with longer
eriods of follow up, as reported by other authors12. In our sample
e did not ﬁnd a signiﬁcant change in weight, TDID or TDID/weight
atio.
The association between the improvement in glucose control
ith CSII and pre-CSII HbA1c was previously reported by Bode15
t al., as well as DeVries16. In concordance with those ﬁndings, we
lso report a negative correlation between pre-CSII HbA1c and its
ariation at 12 months and at the end of follow up.
Women  had better outcomes with CSII than men, and this dif-
erence persisted even when adjusted to pre-CSII HbA1c. In a recent
tudy19, this gender difference was reported, but the authors did
ot ﬁnd a causal explanation for the results.
The fact that women presented with higher pre-CSII HbA1c
alues could be related to the existence of a patient subset with
rittle diabetes20. This classiﬁcation is very controversial and little
nderstood. The results of CSII therapy in brittle diabetes are very
iscordant between studies, some of which report beneﬁt20–24.
owever, it has already been reported improvement in metabolic
ontrol in female adolescents and young adults with CSII therapy18.
attaglia and colleagues considered that the studied population
as a high prevalence of insulin injection omission, particularly in
ndividuals with body image disorders, and showed that CSII was
ssociated with a signiﬁcant improvement in metabolic control,
dherence to the prescribed regimen and better self-efﬁcacy. Occa-
ionally, this type of behavior is not identiﬁed, and these patients’
iabetes is wrongly classiﬁed as brittle.
The response to the intervention in the group of women might
lso be related to other variables, which we did not evaluate,
erhaps associated with the receptivity and adherence to new tech-
ologies, including the appropriate use of an insulin pump. It is also
ossible that there are other variables related to glucose control
hat we cannot infer from pre-CSII HbA1c.
The ﬁnding of a signiﬁcant correlation between pre-CSII TDID
nd its variation at 12 months and at the end of follow up, andbetes Metab. 2015;10(2):128–132 131
with HbA1c variation can hypothetically be related to: 1) the indi-
viduals that most beneﬁted from CSII therapy were already highly
motivated and, beyond the rigorous compliance with their insulin
regimen, they also increasingly adhered to their meal plan, with
subsequent weight loss; 2) individuals that most beneﬁted from
CSII therapy were the ones that had more variability of their needs
of insulin throughout the day and hence, were using a higher TDID
under a MDI  regimen; 3) individuals that most beneﬁted from CSII
therapy are the ones that tend to occasionally neglect insulin injec-
tions and are reported has keeping elevated HbA1c values despite
using higher TDID.
The correlation between age at diagnosis and HbA1c variation
at the end of follow up, and between age at the time of initiation
of CSII and HbA1c variation at 12 months follow up can be related
to the presence of a subset of older individuals in our sample, with
the same duration of diabetes, and less capable of using electronic
devices.
The characterization of two groups in terms of response to
CSII conﬁrmed our previous results, including the ones relative
to a probable gender effect–higher prevalence of women in the
BR group; the inﬂuence of pre-CSII HbA1c–individuals with higher
HbA1c tend to obtain more beneﬁt from CSII; age at diagnosis and at
the time of initiation of the intervention–younger individuals have
more marked reductions in HbA1c.
Limitations
Our study did not include other variables that might inﬂuence
the success of CSII, such as patients’ socioeconomic data (ie edu-
cation level, employment pattern or characterization of the family
aggregate), as this information was  not originally included in our
database. As ours is a convenience sample, we need to consider
selection bias. On the other hand, we did not study the beneﬁts of
CSII in terms of incidence and severity of hypoglycaemia episodes
and incidence of ketoacidosis. We  considered information on
hypoglycaemia unreliable because this was  a retrospective study,
and the registry is frequently based on subjective qualitative
measures of incidence, as determined by several clinicians. On
the other hand, ketoacidosis was  extremely rare. We  were also
not able to extensively characterize the subgroup of women with
greater improvement in metabolic control as our registry did
not include more data on these patients, namely psychometric
measures.
Conclusions
Women  with type 1 diabetes mellitus seem to have greater ben-
eﬁt with CSII therapy, presumably in association with the existence
of a subset of individuals with unsatisfactory glucose control with
multiple daily injections. However, it is possible that other variables
related with the female gender might contribute to this difference.
Our ﬁndings should not interfere with priority criteria for the use
of insulin pumps in type 1 diabetics.
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